Organon completes licensing deal for 99% effective device
Organon (NYSE:OGN) finalized a global licensing agreement with Sebela Pharmaceuticals for a hormone-free birth control device that is 99% effective.
Organon (NYSE:OGN) finalized a global licensing agreement with Sebela Pharmaceuticals for a hormone-free birth control device that is 99% effective.
REGENXBIO (NASDAQ:RGNX) aligned with the FDA to resubmit its rare disease drug application in Q3 2026.
MapLight (NASDAQ:MPLT) announced that its Phase 2 autism trial of 161 patients missed its primary efficacy endpoint.
CRH (NYSE:CRH) signed a definitive agreement to purchase competitor Arcosa for $150 per share in cash.
Fervo Energy (NASDAQ:FRVO) reported a first-quarter net loss of $31.8 million while funding multiple utility-scale geothermal facilities.
Galmed Pharmaceuticals (NASDAQ:GLMD) closed its Colospan acquisition, gaining a device tested on 97 patients.
Definium Therapeutics (NASDAQ:DFTX) stated its depression drug trial succeeded, showing a key 8.1-point improvement over a placebo.
AbbVie (NYSE:ABBV) executed an agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for $135.11 per share in cash, totaling approximately $10.9 billion.
HawkEye 360 (NYSE:HAWK) achieved record first-quarter 2026 revenue of $49.8 million due to strong global demand.
Merck (NYSE:MRK) announced positive topline results from its Phase 3 study evaluating tulisokibart for active ulcerative colitis.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy